Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.12 Analyst target: $9.67 Upside: 209.94%
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company is headquartered in San Jose, California.
See the full interactive analysis & chart →Informational only — not investment advice.